4 unknown, 3 not yet recruiting, 2 completed, 2 terminated. 5 Phase 2, 1 Early Phase 1, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Prostate Cancer Adenocarcinoma: new trials by email Literature Review of Prostate Cancer Adenocarcinoma trials Research Report on Prostate Cancer Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer Validate spatial localization of candidate microbial signals via 16S rRNA ISH, FISH, immunofluorescence, IHC, and spatial omics. - Prostate Cancer Adenocarcinoma | Not yet recruiting | Anhui Medical University | 100 | 2026-10-01 | 2026-09-14 | |
| Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancer Multi-omics profiling - Prostate Cancer Adenocarcinoma | Not yet recruiting | Anhui Medical University | 120 | 2026-10-01 | 2026-09-14 | |
| Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer Standard Endocrine Therapy, LC-K76 - mHSPC, mHNPC | Early Phase 1 | Not yet recruiting | Shanghai Changzheng Hospital | 40 | 2026-02-01 | 2026-02-05 |
| Prostatic Size Reduction Following of Leuprorelin Acetate ACETATE LEUPRELINE - Prostate Cancer Adenocarcinoma, Prostate Adenocarcinoma | Unknown | Consorci Sanitari de Terrassa | 40 | 2024-02-02 | 2024-09-19 | |
| Use of Indocyanine Green in Robotic Prostate Surgeries using Indocyanine Green, Nerve-sparing robot-assisted laparoscopic radical prostatectomy - Prostate Cancer Adenocarcinoma, Erectile Dysfunction Following Radical Prostatectomy | Phase 4 | Unknown | Ankara University | 200 | 2023-07-30 | 2023-07-25 |
| Trial of NanoPac Focal Therapy for Prostate Cancer NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Terminated | NanOlogy, LLC | 1 | 2020-10-20 | 2022-03-29 |
| Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer Cabozantinib, Radical Prostatectomy - Prostate Cancer, Prostate Cancer Adenocarcinoma | Phase 2 | Terminated | Duke University | 3 | 2020-03-17 | 2022-06-29 |
| 18F-DCFPyL PET-CT Scan and Prostate Cancer 18F-DCFPyL - Prostate Cancer Adenocarcinoma | Phase 2 / Phase 3 | Unknown | Lida Jafari | 170 | 2018-07-22 | 2019-02-25 |
| Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) 30Gy (Gray) planning target volume (PTV) - Prostate Cancer Adenocarcinoma | Phase 2 | Active not recruiting | University of Texas Southwestern Medical Center | 124 | 2018-04-24 | 2026-06-05 |
| Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy SBRT - Prostate Cancer Adenocarcinoma, Adjuvant Radiotherapy | Phase 1 | Unknown | Fundacao Champalimaud | 30 | 2016-11-01 | 2019-07-23 |
| Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer Hypo-FLAME study - Prostate Cancer Adenocarcinoma | Phase 2 | Completed | UMC Utrecht | 100 | 2016-04-01 | 2018-12-20 |
| Multi-omics Analysis of Prostate Derived Extracellular Vesicles: an Observational Retrospective Study for Prostate Cancer Diagnosis and Monitoring Prostate Cancer Adenocarcinoma | Completed | IRCCS San Raffaele | 100 | 2016-01-01 | 2026-05-15 |
Prostatic Neoplasms (5) · Erectile Dysfunction (2) · Genital Neoplasms, Male (1) · Urogenital Neoplasms (1)
Genital Diseases (7) · Genital Diseases, Male (7) · Male Urogenital Diseases (7) · Urogenital Diseases (7) · Neoplasms (5) · Neoplasms by Site (5) · Prostatic Diseases (5) · Genital Neoplasms, Male (4) · Urogenital Neoplasms (4) · Mental Disorders (2) · Sexual Dysfunction, Physiological (2) · Sexual Dysfunctions, Psychological (2) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Fluorescent Antibody Technique (1) · Immunohistochemistry (1) · In Situ Hybridization, Fluorescence (1) · Indocyanine Green (1) · Paclitaxel (1) · Powders (1) · Suspensions (1) · cabozantinib (1)
Anhui Medical University (2) · Ankara University (1) · Consorci Sanitari de Terrassa (1) · Duke University (1) · Fundacao Champalimaud (1) · IRCCS San Raffaele (1) · Lida Jafari (1) · NanOlogy, LLC (1) · Shanghai Changzheng Hospital (1) · UMC Utrecht (1) · University of Texas Southwestern Medical Center (1)
United States (4) · China (3) · Belgium (1) · Netherlands (1) · Portugal (1) · Spain (1)
Araz Musaev (1) · Carlo Greco, M.D. (1) · Linda GW Kerkmeijer, MD, PhD (1) · Michael Harrison, MD (1) · Shelagh Verco, PhD (1) · Sheng Tai, M.D. (1)
PMID 38230766, PMID 39036382, PMID 12657927, PMID 17123267, PMID 19484787, PMID 23721958, PMID 23846904, PMID 25387460, PMID 27365449, PMID 28434677, PMID 28912244, PMID 29390991, PMID 29511634, PMID 29567829, PMID 29925878, PMID 30046175, PMID 30497919, PMID 30923225, PMID 31398337, PMID 31611697, PMID 32247206, PMID 32280821, PMID 32467386, PMID 33462506, PMID 33538338, PMID 33766858, PMID 35450835, PMID 36055231, PMID 36912538, PMID 38572751, PMID 39362607